medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 5

<< Back Next >>

Ann Hepatol 2015; 14 (5)

Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19

Barrera F, Azócar L, Molina H, Schalper KA, Ocares M, Liberona J, Villarroel L, Pimentel F, Pérez-Ayuso RM, Nervi F, Groen AK, Miquel JF

Language: English
References: 44
Page: 710-721
PDF size: 348.11 Kb.


ABSTRACT

Background and rationale for the study. FGF19/15 is a gut-derived hormone presumably governing bile acid (BA) synthesis and gallbladder (GB) refilling. FGF19 mRNA is present in human GB cholangiocytes (hGBECs); however, the physiological significance of GB-derived FGF19 remains unknown. We investigated whether hGBECs secrete FGF19 and the effects of cholecystectomy on serum FGF19 ([FGF19]s) and BA synthesis. Material and methods. FGF19 expression was assessed by qRT-PCRs and immunostaining in hGBECs and terminal ileum, and quantified in bile and serum by ELISA. Basal and BA (chenodexycholic acid, CDCA) induced FGF19 expression and secretion was analyzed in primary cultured hGBECs and GB-d1 cell line. Pre and postprandial serum changes in [FGF19]s, 7α-hydroxy-4-cholestene-3-one (C4, a marker of BA synthesis) and BA were evaluated in plasma of gallstone disease patients at baseline and after cholecystectomy. Results. FGF19 mRNA levels were ~250-fold higher in hGBECs compared to distal ileum. GB bile contained ~23-fold higher FGF19 levels compared to serum (p ‹ 0.0001). CDCA induced dose-dependent expression and secretion of FGF19 in hGBECs and GB-d1 cells. Cholecystectomy increased plasma BA synthesis ≥ 2-fold (p ‹ 0.0001), and altered the diurnal rhythm and significantly reduced [FGF19]s noon peak. BA serum levels, serum cholesterol and triglyceride content remained unchanged. Conclusions. In conclusion human GB cholangiocytes constitutively express and secrete high levels of FGF19 in a process regulated by BA. Resection of this organ doubles BA synthesis concomitantly with changes in [FGF19]s. These findings suggest a potential connection between GB cholangiocytes-derived FGF19 and BA metabolism that could lead to metabolic dysregulation following cholecystectomy.


REFERENCES

  1. Itoh N. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res 2010; 342: 1-11.

  2. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, Mc- Donald JG, Luo G, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-25.

  3. Choi M, Moschetta A, Bookout AL, Peng L, Umetani M, Holmstrom SR, Suino-Powell K, et al. Identification of a hormonal basis for gallbladder filling. Nat Med 2006; 12: 1253-5.

  4. Li J, Pircher PC, Schulman IG, Westin SK. Regulation of complement C3 expression by the bile acid receptor FXR. J Biol Chem 2005; 280: 7427-34.

  5. Stroeve JH, Brufau G, Stellaard F, Gonzalez FJ, Staels B, Kuipers F. Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice. Lab Invest 2010; 90: 1457-67.

  6. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003; 17: 1581-91.

  7. Lundasen T, Galman C, Angelin B, Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 260: 530-6.

  8. Schreuder TC, Marsman HA, Lenicek M, van Werven JR, Nederveen AJ, Jansen PL, Schaap FG. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 2010; 298: G440-G445.

  9. Brufau G, Stellaard F, Prado K, Bloks VW, Jonkers E, Boverhof R, Kuipers F, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 2010; 52: 1455-64.

  10. Galman C, Angelin B, Rudling M. Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. J Intern Med 2011; 270: 580-8.

  11. Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators—a critical appraisal. Cell Metab 2012; 16: 693-705.

  12. Jones S. Mini-review: endocrine actions of fibroblast growth factor 19. Mol Pharm 2008; 5: 42-8.

  13. Strack AM, Myers RW. Modulation of metabolic syndrome by fibroblast growth factor 19 (FGF19)? Endocrinology 2004; 145: 2591-3.

  14. Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143: 1741-7.

  15. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004; 145: 2594-603.

  16. Kim-Muller JY, Accili D. Cell biology. Selective insulin sensitizers. Science 2011; 331: 1529-31.

  17. Xie MH, Holcomb I, Deuel B, Dowd P, Huang A, Vagts A, Foster J, et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999; 11: 729-35.

  18. Miquel JF, Moreno M, Amigo L, Molina H, Mardones P, Wistuba, II, Rigotti A. Expression and regulation of scavenger receptor class B type I (SR-BI) in gall bladder epithelium. Gut 2003; 52: 1017-24.

  19. Erranz B, Miquel JF, Argraves WS, Barth JL, Pimentel F, Marzolo MP. Megalin and cubilin expression in gallbladder epithelium and regulation by bile acids. J Lipid Res 2004; 45: 2185-98.

  20. Dray-Charier N, Paul A, Combettes L, Bouin M, Mergey M, Balladur P, Capeau J, et al. Regulation of mucin secretion in human gallbladder epithelial cells: predominant role of calcium and protein kinase C. Gastroenterology 1997; 112: 978-990.

  21. Mukai S, Miyazaki K, Yakushiji H. The role of E-cadherin in the differentiation of gallbladder cancer cells. Cell Tissue Res 2001; 306: 117-28.

  22. Song KH, Li T, Owsley E, Strom S, Chiang JY. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 2009; 49: 297-305.

  23. Portincasa P, Moschetta A, Colecchia A, Festi D, Palasciano G. Measurements of gallbladder motor function by ultrasonography: towards standardization. Dig Liver Dis 2003; 35(Suppl. 3): S56-S61.

  24. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-74.

  25. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44: 1049-60.

  26. Team RDC. R: A language and environment for statistical computing. In. 2.11.1 ed. Vienna: R Foundation for Statistical Computing; 2010.

  27. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007; 282: 26687-95.

  28. Zweers SJ, Booij KA, Komuta M, Roskams T, Gouma DJ, Jansen PL, Schaap FG. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology 2012; 55: 575-83.

  29. Sinha J, Chen F, Miloh T, Burns RC, Yu Z, Shneider BL. beta-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes. Am J Physiol Gastrointest Liver Physiol 2008; 295: G996-G1003.

  30. Galman C, Arvidsson I, Angelin B, Rudling M. Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy- 4-cholesten-3-one in peripheral blood. J Lipid Res 2003; 44: 859-66.

  31. Galman C, Miquel JF, Perez RM, Einarsson C, Stahle L, Marshall G, Nervi F, et al. Bile acid synthesis is increased in Chilean Hispanics with gallstones and in gallstone high-risk Mapuche Indians. Gastroenterology 2004; 126: 741-8.

  32. Desnoyers LR, Pai R, Ferrando RE, Hotzel K, Le T, Ross J, Carano R, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008; 27: 85-97.

  33. Xu YF, Yang XQ, Lu XF, Guo S, Liu Y, Iqbal M, Ning SL, et al. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma. Biochem Biophys Res Commun 2014; 446: 54-60.

  34. Sauter GH, Moussavian AC, Meyer G, Steitz HO, Parhofer KG, Jungst D. Bowel habits and bile acid malabsorption in the months after cholecystectomy. Am J Gastroenterol 2002; 97: 1732-5.

  35. Yarandi SS, Hebbar G, Sauer CG, Cole CR, Ziegler TR. Diverse roles of leptin in the gastrointestinal tract: modulation of motility, absorption, growth, and inflammation. Nutrition 2011; 27: 269-75.

  36. Navar LG, Kobori H, Prieto MC, Gonzalez-Villalobos RA. Intratubular renin-angiotensin system in hypertension. Hypertension 2011; 57: 355-62.

  37. Berr F, Stellaard F, Pratschke E, Paumgartner G. Effects of cholecystectomy on the kinetics of primary and secondary bile acids. J Clin Invest 1989; 83: 1541-50.

  38. Sweeting J. Effect of cholecystectomy on bile acid kinetics. Gastroenterology 1989; 97: 1593-4.

  39. LaRusso NF, Korman MG, Hoffman NE, Hofmann AF. Dynamics of the enterohepatic circulation of bile acids. Postprandial serum concentrations of conjugates of cholic acid in health, cholecystectomized patients, and patients with bile acid malabsorption. N Engl J Med 1974; 291: 689-92.

  40. Almond HR, Vlahcevic ZR, Bell CC, Gregory DH, Swell L. Bile Acid Pools, Kinetics and Biliary Lipid Composition before and after Cholecystectomy. N Eng J Med 1973; 289: 1213-6.

  41. Kullak-Ublick GA, Paumgartner G, Berr F. Long-term effects of cholecystectomy on bile acid metabolism. Hepatology 1995; 21: 41-5.

  42. Amigo L, Husche C, Zanlungo S, Lutjohann D, Arrese M, Miquel JF, Rigotti A, et al. Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice. Liver Int 2011; 31: 52-64.

  43. Ruhl CE, Everhart JE. Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population. Am J Gastroenterol 2013; 108: 952-8.

  44. Nervi F, Arrese M. Cholecystectomy and NAFLD: does gallbladder removal have metabolic consequences? Am J Gastroenterol 2013; 108: 959-61.




2020     |     www.medigraphic.com